-
Mashup Score: 1Login - Integrity CE - 16 hour(s) ago
Username* Password* Remember me Register | Forgot Password
Source: integrityce.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Belantamab + Standard of Care for Newly Diagnosed Myeloma (DreaMM-9) | Saad Usmani, MD | #ASH24 - 16 hour(s) ago
Dr Saad Usmani discusses a study looking at belantamab combined with the standard of care for newly diagnosed multiple myeloma. Link to ASH playlist: https:/…
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet-
RT @MyelomaTeacher: Belantamab + Standard of Care for Newly Diagnosed Myeloma (DreaMM-9) | ... https://t.co/DRyxbkdVQU @szusmani @MSKCanc…
-
-
Mashup Score: 8Paper: Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee - 1 month(s) ago
Program: Oral and Poster Abstracts Session: 907. Outcomes Research: Plasma Cell Disorders: Poster III Hematology Disease Topics & Pathways: Adult, Bispecific Antibody Therapy, Biological therapies, Treatment Considerations, Adverse Events, Study Population, Human Carlyn Rose Tan, MD 1, Sireesha Asoori, MBBS, MPH 2 *, David Nemirovsky 3 *, Andriy Derkach, PhD 3 *, Larissa Brunaldi 4 *, Rakesh Popat 5, Chris Lau 5 *, Efstathios Kastritis, MD 6 *, Joaquín Martínez-Lopez 7 *, Radhika Bansal, MBBS 4 *, Andre
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
@VincentRK The IMWG RWE papers are in the works , being presented here at #ASH24 as well @CarlynRTanMD @HiraSMian @TomBmt133 @YiLinMDPhD et al, first ones with Tec. https://t.co/OgEHzGEolJ https://t.co/ShSU9ngmgU
-
-
Mashup Score: 12
Program: Oral and Poster Abstracts Type: Oral Session: 654. Multiple Myeloma: Pharmacologic Therapies: Targeting BCMA Hematology Disease Topics & Pathways: Research, Clinical trials, Antibody Therapy, Clinical Research, Plasma Cell Disorders, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies Marc S. Raab, M.D. 1 *, Niels Weinhold, PhD 2 *, K. Martin Kortüm, MD 3 *, Jan Krönke, MD 4,5, Lilli Podola 6 *, Uta Bertsch, MD 6 *, Jan H. Frenking, MD 2 *, Julia Mersi, MD 7 *,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
- 493 Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial https://t.co/5MtpL2UkzX - 494 Phase 3 Study of Teclistamab (Tec) in Combination… https://t.co/wARGeRry8W
-
-
Mashup Score: 11
Program: Oral and Poster Abstracts Type: Oral Session: 654. Multiple Myeloma: Pharmacologic Therapies: Optimizing Therapy in Newly Diagnosed Myeloma and Beyond Hematology Disease Topics & Pathways: Research, Clinical trials, Clinical Research, Plasma Cell Disorders, Diseases, Lymphoid Malignancies Gordon Cook, PhD, DSc 1,2 *, Charlotte Pawlyn, PhD 3, Kara-Louise Royle 4 *, Ethan R Senior 5 *, Dax Everritt 6 *, Jenny Bird 7 *, Stella Bowcock 8 *, Bryony Dawkins, MSc 9 *, Mark Drayson 10 *, Sharon Gillson,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
- 673 IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial https://t.co/kKMlFqbifx - 769 Isatuximab, Lenalidomide, Bortezomib and… https://t.co/tgdSdi5UrC
-
-
Mashup Score: 5
Program: Oral and Poster Abstracts Type: Oral Session: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Uncovering New Targets and Disease Mechanisms in Myeloma Hematology Disease Topics & Pathways: Research, Translational Research, Genomics, Biological Processes, Pathogenesis Kylee H Maclachlan, PhD, BSc, FRACP, FRCPA 1, Marios Papadimitriou 2 *, Patrick Blaney, MS 3 *, Tala Shekarkhand, MS 4 *, Timothy R. Chu, MS 5 *, Alexandra Maria Poos, PhD 6 *, Elizabeth Brown 7 *, Antje
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
- 766 Whole Genome Sequencing Reveals Lower Apobec-Mutational Activity in Multiple Myeloma Patients with African Ancestry Compared with Those Having European Ancestry https://t.co/sOL5wV1dVx - 592 Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of… https://t.co/HNzPQJHoEQ
-
-
Mashup Score: 17Paper: A 1,000-Genome Map for Multiple Myeloma and Its Precursor Stages, and Its Impact on Clinical Outcome - 1 month(s) ago
Program: Oral and Poster Abstracts Type: Oral Session: 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Genes, Cells and Algorithms: Novel Methods of Predicting Progression in MGUS and SMM Hematology Disease Topics & Pathways: Research, Translational Research, Bioinformatics, Genomics, Computational biology, Biological Processes, Technology and Procedures, Omics technologies Jean-Baptiste Alberge, PhD 1,2,3, Ankit K. Dutta, PhD 1,2,3 *, Andrea Poletti 1,4
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
**Basic/Translational Abstracts: - 1019 A 1,000-Genome Map for Multiple Myeloma and Its Precursor Stages, and Its Impact on Clinical Outcome https://t.co/oSbzH0CDX6 -358 Combination with Cytotoxic Therapy and Checkpoint Blockade Overcomes Primary Resistance to BCMA Bispecific… https://t.co/MTRou3ET7G
-
-
Mashup Score: 3Paper: Genomic Complexity Correlates with the Degree of Marrow Independence of Malignant Plasma Cells in the Context of Extramedullary Disease - 1 month(s) ago
Program: Oral and Poster Abstracts Type: Oral Session: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Genomic and Epigenomic Insights into Myeloma Outcomes Hematology Disease Topics & Pathways: Research, Translational Research, Genomics, Biological Processes Kylee H Maclachlan, PhD, BSc, FRACP, FRCPA 1, Juan-Jose Garces, PhD 2 *, Tala Shekarkhand, MS 3 *, Sridevi Rajeeve, MD 1 *, Hamza Sloan Hashmi, MD 3 *, Hani Hassoun, MD 3, Malin Hultcrantz, MD 3, Neha Korde, MD 3, Carlyn
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
- 248 Genomic Complexity Correlates with the Degree of Marrow Independence of Malignant Plasma Cells in the Context of Extramedullary Disease https://t.co/uPI3nGpgqJ - 251 DNA Methylation Analysis of Commpass Reveals Distinct Epigenetic Programs of High-Risk Disease… https://t.co/MZUDB2yUS9
-
-
Mashup Score: 12
Program: Oral and Poster Abstracts Type: Oral Session: 654. Multiple Myeloma: Pharmacologic Therapies: Targeting BCMA Hematology Disease Topics & Pathways: Research, Clinical trials, Antibody Therapy, Clinical Research, Plasma Cell Disorders, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies Marc S. Raab, M.D. 1 *, Niels Weinhold, PhD 2 *, K. Martin Kortüm, MD 3 *, Jan Krönke, MD 4,5, Lilli Podola 6 *, Uta Bertsch, MD 6 *, Jan H. Frenking, MD 2 *, Julia Mersi, MD 7 *,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
- 493 Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial https://t.co/5MtpL2UkzX - 494 Phase 3 Study of Teclistamab (Tec) in Combination… https://t.co/wARGeRry8W
-
-
Mashup Score: 33MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma - PubMed - 2 month(s) ago
In newly diagnosed multiple myeloma (NDMM), measurable residual disease (MRD) status is prognostically important, but its role in treatment-decisions remains unclear. In a phase II trial (NCT04113018), we assessed daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd) induction followed …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
A big shoutout to @LevineCancer #mmsm crew for bringing this study to fruition. @manisha_bhutani @PlasmaCellPete @AtrashShebli @BarryAdamP 😊🙏🏽👏🏽👏🏽👏🏽👏🏽 https://t.co/cr8r0dUDre
-
RT @SoMeCME: 6/ We hope you enjoyed this #MMBrief! Complete the posttest & evaluation here 👉 https://t.co/iK4QKBGsaM & claim your 🆓 CME!…